展望：抗生素研发中的利润问题。

Outlook: the profit problem in antibiotic R&D.

作者信息

Nathan Carl, Goldberg Frederick M

机构信息

Department of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Avenue, New York, New York 10021, USA.

出版信息

Nat Rev Drug Discov. 2005 Nov;4(11):887-91. doi: 10.1038/nrd1878.

DOI:10.1038/nrd1878

PMID:16247440

Abstract

Economists, a biomedical researcher and a business executive have formulated three contrasting proposals to address the shortfall in antibiotic R&D. Their proposals, which emphasize advance purchase contracts, not-for-profit research, and tax incentives, respectively, share some features with provisions in bills pending before the US Congress that could potentially reshape the R&D landscape for this essential class of drugs.

摘要

一位经济学家、一位生物医学研究人员和一位企业高管提出了三项截然不同的提议，以应对抗生素研发资金短缺的问题。他们的提议分别强调预购合同、非营利性研究和税收激励措施，这些提议与美国国会正在审议的法案中的条款有一些共同之处，这些条款可能会重塑这类重要药物的研发格局。